KURN Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.…
Industry Peers
Medical DevicesKey Statistics
About Kuros Biosciences (SWX: KURN)
›
Kuros Biosciences (SWX: KURN) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 213 employees.
The shares were at 18.78 CHF on 20 November 2026, down 31.2% over 52 weeks. Its 52-week range is 16.46 CHF to 32.48 CHF: the price is 42.2% below the high and 14.1% above the low.
At a market capitalisation of 746.63M CHF, it trades at 110.5 times trailing earnings and 34.0 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 333% for KURN.
Kuros Biosciences reports return on equity of 3.0%, an operating margin of 6.1% and revenue up 45.5% year over year.
Its debt exceeds its cash by 334.00K USD, a debt-to-equity ratio of 0.02. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 34.33 CHF is 82.8% above the current price. The next earnings report is expected on 3 March 2027.